Zhang Ying-Ying, Xia Ru-Yu, Liang Shi-Bing, Hu Xiao-Yang, Dai Meng-Yuan, Li Yi-Lin, Zhao Le-Yi, Moore Michael, Fei Yu-Tong, Liu Jian-Ping
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
School of Primary Care, Population Sciences, and Medical Education, University of Southampton, Southampton, United Kingdom.
Integr Med Res. 2021 Sep;10(3):100726. doi: 10.1016/j.imr.2021.100726. Epub 2021 Apr 2.
Shufeng Jiedu capsule has been widely used in China for acute upper respiratory tract infections (AURTIs). The aim of this study was to evaluate its effectiveness and safety for AURTIs.
Randomized controlled trials comparing SFJD with conventional drug for patients with AURTIs were included. Eight databases were searched from their inceptions to February 2021. Data was synthesized using risk ration (RR) or mean difference (MD) with their 95% confidence interval (CI). The primary outcome was resolution time of typical symptoms.
Twenty-five RCTs involving 3410 patients were included. SFJD in combination with conventional drug was associated with; in common cold shortening the duration of fever (MD -1.54 days, 95% CI [-2.15,-0.92], = 80%, = 385, 3 trials) and cough (MD -1.22 days, 95% CI [-1.52, -0.93]); in herpangina, shortening the duration of fever (MD -0.68 days, 95% CI [-1.15, -0.21], = 68%, = 140, 2 trials) and blistering (MD -0.99 days, 95% CI [-1.23, -0.76], = 386, 3 trials); in acute tonsillitis and acute pharyngitis shortening the duration of fever (MD -1.13 days, 95% CI [-1.36, -0.90], = 33%, = 688, 7 trials) and sore throat (MD -1.13 days, 95% CI [-1.40, -0.86], = 84.1%, = 1194, 10 trials). SFJD also improving their cure rate with a range (1-5 days). No serious adverse events were reported.
Low certainty evidence suggests that SFJD appears to shorten the duration of symptoms in AURTIs, improve cure rate and seems safe for application. However, high quality placebo controlled trials are warranted to confirm its benefit.
疏风解毒胶囊在中国已广泛用于治疗急性上呼吸道感染（AURTIs）。本研究旨在评估其治疗AURTIs的有效性和安全性。
纳入比较疏风解毒胶囊（SFJD）与传统药物治疗AURTIs患者的随机对照试验。检索了8个数据库，时间跨度从建库至2021年2月。采用风险比（RR）或均值差（MD）及其95%置信区间（CI）进行数据合成。主要结局指标为典型症状的缓解时间。
纳入25项随机对照试验，共3410例患者。SFJD联合传统药物可使：普通感冒患者发热持续时间缩短（MD -1.54天，95%CI[-2.15,-0.92]，I² = 80%，n = 385，3项试验）、咳嗽持续时间缩短（MD -1.22天，95%CI[-1.52,-0.93]）；疱疹性咽峡炎患者发热持续时间缩短（MD -0.68天，95%CI[-1.15,-0.21]，I² = 68%，n = 140，2项试验）、疱疹持续时间缩短（MD -0.99天，95%CI[-1.23,-0.76]，n = 386，3项试验）；急性扁桃体炎和急性咽炎患者发热持续时间缩短（MD -1.13天，95%CI[-1.36,-0.90]，I² = 33%，n = 688，7项试验）、咽痛持续时间缩短（MD -1.13天，95%CI[-1.40,-0.86]，I² = 84.1%，n = 1194，10项试验）。SFJD还能在一定范围（1 - 5天）内提高治愈率。未报告严重不良事件。
低确定性证据表明，SFJD似乎可缩短AURTIs的症状持续时间，提高治愈率，且应用似乎安全。然而，需要高质量的安慰剂对照试验来证实其益处。
